HCG

HCG Research Material: Human Chorionic Gonadotropin Guide

Researchers use HCG research material to study human chorionic gonadotropin, a heterodimeric glycoprotein hormone composed of an alpha subunit shared with several other glycoprotein hormones and a beta subunit that provides much of HCG’s biological and immunological specificity. HCG is not a short synthetic peptide. Moreover, its folding, subunit assembly, disulfide bonds, glycosylation, source, and molecular heterogeneity all influence how a preparation behaves in immunochemical and functional assays.

This listing covers laboratory research exclusively, including immunoassay development, analytical characterization, LHCGR receptor-signaling studies, potency-method comparison, glycoform research, and quality-control experiments. Specifically, the vial designations are supply potencies expressed in International Units (IU), not mass amounts and not administration instructions. However, Hanpro does not supply this product for pregnancy testing, patient-result interpretation, fertility treatment, weight loss, bodybuilding, injection, diagnosis, or human or animal use.

Molecular and Product Overview

Product name	HCG / human chorionic gonadotropin research material
Molecule class	Heterodimeric, extensively glycosylated protein hormone; not a conventional short peptide
Subunits	Common glycoprotein-hormone alpha subunit (CGA) plus HCG beta subunit (CGB)
Primary receptor studied	Luteinizing hormone/choriogonadotropin receptor (LHCGR), a G-protein-coupled receptor
Approximate molecular size	Commonly reported near 37 kDa, with variation caused by glycosylation and molecular form
Listing configurations	5,000 IU × 10 vials or 10,000 IU × 10 vials
Potency unit	International Units referenced to an appropriate biological standard; IU is not interchangeable with mass
Suggested analytical approaches	Immunoassay, receptor or cell-based bioassay, SEC, electrophoresis, isoelectric focusing, peptide mapping, intact-mass and glycan analysis
Documentation	Review lot-specific source, identity, potency method, excipients, purity profile, and certificate of analysis
Use restriction	Laboratory research only; not for diagnosis or human or animal administration

A product name and IU label alone cannot adequately characterize a protein-hormone preparation. For example, two lots with the same nominal IU may differ in immunoreactivity, bioactivity, aggregation, free-subunit content, glycoform distribution, excipients, or analytical response. Therefore, researchers should define the molecular form and the calibration chain required for their method before assigning equivalence between materials.

HCG Structure and Molecular Heterogeneity

The active intact hormone contains noncovalently associated alpha and beta subunits, with characteristic intrachain disulfide bonds stabilizing each chain. In addition, the alpha chain closely resembles the alpha subunits of luteinizing hormone, follicle-stimulating hormone, and thyroid-stimulating hormone. Meanwhile, the beta chain supplies distinctive epitopes and contains a C-terminal extension with additional glycosylation. Therefore, this architecture makes antibody epitope selection a major determinant of assay specificity.

HCG exists as a family of molecular forms rather than one perfectly uniform species. For example, researchers may encounter intact hormone, nicked molecules, free beta subunit, beta-core fragment, free alpha subunit, and glycoforms with different carbohydrate composition or sialylation. Moreover, source and processing can alter that distribution. Therefore, researchers should not automatically compare a result from an intact-HCG sandwich assay with a total-beta assay or receptor bioassay.

Glycosylation affects folding, stability, receptor activation, clearance, charge, and assay recognition. Specifically, a change in sialic-acid content can shift isoelectric behavior and may alter in-vitro bioactivity differently from behavior in a whole organism. Consequently, deglycosylated protein, recombinant material, urinary material, and a WHO reference preparation may not be commutable across all measurement systems.

Mechanisms and Pathways Studied with HCG

1. LHCGR Binding and Gs/cAMP Signaling

HCG is a ligand for LHCGR, a class A G-protein-coupled receptor. In responsive experimental systems, receptor engagement can activate Gs, adenylate cyclase, cyclic AMP, and protein kinase A. For example, common research readouts include cAMP accumulation, reporter-gene activation, receptor internalization, phosphorylation, and downstream steroidogenic-gene expression. However, cell background, receptor density, glycoform composition, and exposure time can substantially change the response.

2. Receptor Desensitization and Trafficking

Like other GPCR systems, LHCGR can undergo phosphorylation, beta-arrestin recruitment, internalization, recycling, and degradation. Moreover, ligand concentration and exposure pattern can influence whether a study measures an acute signaling event or a desensitized state. Consequently, imaging, surface-receptor quantification, and time-resolved signaling help distinguish these processes from simple loss of cell viability.

3. ERK, Akt, and Context-Dependent Signaling

Beyond the canonical cAMP pathway, experimental models have reported engagement of MAPK/ERK, PI3K/Akt, and other signaling networks. However, these pathways are not unique to LHCGR, so researchers need pathway inhibitors, receptor-negative cells, genetic controls, and orthogonal endpoints before attributing a change specifically to HCG. Likewise, responses in engineered cell lines may not reproduce those of primary cells.

4. Subunit Specificity and Immunoreactivity

The shared alpha subunit creates potential cross-reactivity with related glycoprotein hormones, while the beta subunit provides more specific epitopes. Therefore, assay developers often use two antibodies recognizing distinct regions to favor detection of intact HCG. By contrast, other formats intentionally measure free beta or broader sets of beta-containing forms. Accordingly, experimental conclusions must state exactly which molecular forms the antibodies recognize.

5. Glycoform-Dependent Bioactivity

Differences in carbohydrate branching, fucosylation, sialylation, and terminal residues can influence charge, receptor interaction, stability, and immunoassay recovery. For example, researchers can pair glycan profiling with cell-based bioactivity to study structure-function relationships. Accordingly, they should interpret a chromatographic shift or altered cAMP response against a qualified control rather than assume that it reflects higher or lower purity.

6. Trophoblast and Placental Biology Models

Researchers associate endogenous HCG with trophoblast and placental biology and use models to examine secretion, molecular forms, receptor signaling, cell differentiation, and assay biomarkers. However, a commercial research preparation can serve as a calibrator or stimulus only after researchers characterize its source and molecular composition. Consequently, this product page does not provide clinical pregnancy interpretation or diagnostic decision thresholds.

7. Potency and Standardization

The WHO International Standard for chorionic gonadotrophin illustrates why researchers must tie potency to a defined method. Specifically, the NIBSC documentation assigns different numerical unitages for immunoassay calibration and for bioassay-based potency. Therefore, that distinction is central to HCG research: an IU value is operationally defined and does not describe a universal number of molecules or a direct mass conversion for every preparation.

Appropriate Research Applications

Immunoassay Development and Cross-Reactivity

Researchers use HCG materials to evaluate capture and detection antibodies, calibration curves, analytical sensitivity, dilution linearity, hook effect, recovery, specificity, and interference. For example, panels should include intact HCG, free subunits, related glycoprotein hormones, matrix blanks, and relevant fragments where available. Accordingly, an assay’s result is meaningful only for the molecular forms defined by its antibody pair and calibration system.

Cell-Based LHCGR Bioassays

Researchers can use engineered or endogenous LHCGR-expressing cells to compare functional potency. Specifically, a robust design includes receptor-negative controls, a qualified reference preparation, vehicle controls, replicate concentration-response curves, predefined curve-fitting rules, and system-suitability criteria. Therefore, results should report relative potency with confidence intervals rather than only a single-point response.

Glycoprotein Characterization

Researchers can investigate intact mass, subunit composition, aggregation, charge variants, glycan profiles, disulfide integrity, and degradation. Likewise, size-exclusion chromatography, capillary or gel electrophoresis, ion-exchange methods, isoelectric focusing, LC-MS peptide mapping, released-glycan analysis, and lectin-based methods provide complementary information. Therefore, no single test establishes identity, purity, and bioactivity simultaneously.

Reference-Material and Commutability Studies

A candidate calibrator may behave differently across immunoassays or between immunochemical and biological methods. Therefore, commutability studies compare the candidate with representative samples across multiple systems. In addition, teams must document the chosen WHO or other recognized reference material, traceability chain, matrix, uncertainty, and intended use. However, researchers should not assume that a store product replaces an official reference standard.

Stability and Degradation Research

Forced-degradation and real-time studies can examine temperature, light, agitation, oxidation, pH, adsorption, freeze-thaw exposure, or storage duration. For example, readouts may include loss of immunoreactivity, change in relative potency, aggregation, fragmentation, charge shift, or glycan alteration. Consequently, researchers should establish stability for the actual container, concentration, buffer, and analytical method.

Analytical and Quality-Control Framework

1. Document provenance. Record supplier, lot, source or expression system if disclosed, manufacturing date, container condition, excipients, and storage history.
2. Confirm molecular identity. Use orthogonal evidence such as immunoreactivity plus peptide mapping, intact/subunit mass, or sequence-supporting MS.
3. Assess size and aggregation. Apply SEC and nonreducing/reducing electrophoresis or a suitable capillary method to distinguish intact material, subunits, fragments, and aggregates.
4. Characterize charge and glycosylation. Use isoelectric or ion-exchange methods and fit-for-purpose glycan analysis when glycoform distribution matters.
5. Measure functional potency. Compare a validated LHCGR-dependent cell bioassay with a qualified reference and report uncertainty.
6. Evaluate assay-specific purity. State what the method detects; area percentage from one chromatogram is not a universal protein-purity value.
7. Check system-relevant impurities. Excipients, residual host-cell components, bioburden, endotoxin, and particulates may matter depending on the model, but must be tested rather than assumed.
8. Retain samples and raw data. Preserve chromatograms, spectra, plate maps, images, instrument methods, integration settings, and reserve aliquots under controlled conditions.

Laboratory Handling and Stability

Treat HCG research material as a biologically active protein of lot-dependent and potentially biological origin. Qualified personnel should complete a written risk assessment, wear laboratory-appropriate personal protective equipment, avoid generating aerosols, and prevent contact with skin, eyes, food, medicines, or clinical supplies. Review the certificate and safety documentation before opening the vial.

Follow the lot-specific storage statement rather than copying conditions from a reference-standard leaflet or a licensed medicine. In addition, protect protein material from unnecessary heat, moisture, light, agitation, adsorption, and repeated temperature cycling. If teams prepare analytical solutions, they should record buffer, pH, concentration, container material, preparation time, storage conditions, and freeze-thaw history. Finally, validate stability in the actual method.

This page intentionally provides no injection, administration, fertility-treatment, pregnancy-testing, or patient-interpretation instructions. Specifically, the listed 5,000 IU and 10,000 IU configurations are container potencies, not recommended doses. Therefore, never administer the material to a person or animal, use it in a diagnostic procedure, or substitute it for an approved medicine or certified diagnostic calibrator.

Frequently Asked Questions

1. What is HCG?

Human chorionic gonadotropin is a glycosylated heterodimeric hormone containing alpha and beta subunits. It is much larger and more structurally complex than a short synthetic peptide. In laboratory research it is used for receptor, immunoassay, glycoform, bioactivity, and standardization studies.

2. Is HCG measured by mass or by IU?

Both types of measurement can exist, but they are not interchangeable without a defined reference and method. Specifically, International Units express assigned biological or immunochemical activity relative to a standard. By contrast, mass measures material quantity. Moreover, glycoforms and molecular fragments may contribute differently to each assay.

3. Why can two HCG assays give different results?

Antibodies may recognize intact hormone, free beta subunit, beta-core fragment, nicked forms, or different epitopes. In addition, calibration, matrix, interference, and glycoform composition differ. Therefore, assay comparison requires molecular-form definitions, traceability information, and commutability testing.

4. What does HCG activate in a cell model?

HCG primarily engages LHCGR. For example, a common early readout is Gs-dependent cAMP production, followed by protein-kinase-A-linked responses. Researchers may also study ERK, Akt, receptor trafficking, and beta-arrestin pathways, but interpretation requires receptor-specific controls.

5. How should researchers verify an HCG lot?

Use orthogonal methods that address identity, size, aggregation, charge or glycosylation, immunoreactivity, and functional potency. Compare with a qualified reference and document method performance. A certificate of analysis alone does not establish suitability for every assay.

6. How should HCG research material be stored?

Use the lot-specific label and certificate, because formulation and source may differ. In addition, minimize heat, moisture, light, agitation, contamination, and repeated temperature cycling. Finally, researchers should demonstrate the stability of any prepared analytical solution under its real buffer, container, and storage conditions.

7. Can this HCG product be used for pregnancy testing or treatment?

No. Hanpro sells it only for laboratory research. Specifically, it is not a diagnostic device, certified clinical calibrator, prescription medicine, fertility product, weight-loss product, or material for human or animal administration. Therefore, questions about patient testing or treatment belong with qualified healthcare professionals and approved products.

Related Research Materials

• Kisspeptin — a neuroendocrine research peptide associated with hypothalamic signaling models.
• Oxytocin Acetate — a peptide-hormone research material for receptor and signaling studies.
• VIP — a neuropeptide used in receptor, barrier, and immunoregulatory research.
• Follistatin — an activin-binding protein research material for signaling studies.
• IGF-1 LR3 — an IGF-pathway research analogue for receptor and cell-response models.
• Sermorelin Acetate — a GHRH-derived research peptide.
• Tesamorelin — a stabilized GHRH analogue for laboratory endocrine-pathway research.
• Ipamorelin — a ghrelin-receptor agonist research peptide.
• CJC-1295 Without DAC — a modified GRF research peptide for endocrine signaling models.
• PT-141 — a melanocortin-receptor research peptide.

Quality Documentation

Hanpro Peptides supplies materials for qualified research laboratories. Lot evaluation may include identity testing, protein-profile assessment, potency measurement, visual inspection, and documentation review. Exact methods and specifications can vary by material and lot. Researchers should request the applicable certificate of analysis and determine whether its calibration, reference standard, acceptance criteria, and uncertainty are suitable for the intended assay.

Receiving laboratories remain responsible for independent identity verification, method suitability, biosafety review, chain of custody, storage qualification, and regulatory compliance. Do not infer sterile status, clinical grade, diagnostic suitability, endotoxin status, biological source, or absence of specific impurities unless the lot documentation explicitly tests and supports that property.

Selected Authoritative References

1. U.S. Food and Drug Administration. Guidance for over-the-counter human chorionic gonadotropin 510(k)s, including molecular forms and assay-specificity considerations. Read the guidance.
2. WHO/NIBSC. 5th International Standard for Chorionic Gonadotrophin, NIBSC code 07/364, with assigned immunoassay and bioassay unitages. Read the instructions for use.
3. UniProtKB P01215. Human glycoprotein hormones alpha chain (CGA). View the reviewed protein record.
4. UniProtKB P0DN86. Human choriogonadotropin beta subunit (CGB). View the reviewed protein record.
5. NCBI Gene 3973. Human luteinizing hormone/choriogonadotropin receptor (LHCGR). View the gene record.
6. U.S. FDA. Current prescribing-information example for an approved chorionic gonadotropin product, illustrating that clinical products have specific indications, contraindications, warnings, and monitoring requirements. View the label.

Research-use disclaimer: This HCG material is supplied exclusively for nonclinical laboratory research by qualified professionals. It is not a medicine, diagnostic device, pregnancy test, food, dietary supplement, cosmetic, or veterinary product. It is not for injection, ingestion, weight loss, fertility treatment, diagnosis, patient-result interpretation, or human or animal administration. Nothing on this page is medical advice. Investigators are responsible for biosafety assessment, ethics and legal review, method validation, safe disposal, and compliance with all applicable institutional and jurisdictional requirements.